

# Media release

## Trial shows using two drugs not better than one when treating MRSA blood infections

Researchers attempting to improve the treatment for methicillin-resistant *Staphylococcus aureus* (MRSA) blood infections have discovered the combination of two antibiotics was no better than one, and led to more adverse effects.

MRSA bloodstream infections have a mortality rate between 20 and 25 per cent and cause around 1000 infections a year in Australia.

In what is the biggest trial of MRSA bloodstream infections to date (352 participants from Australia, Singapore, New Zealand and Israel), the CAMERA2<sup>1</sup> clinical trial, researchers from the Menzies School of Health Research (Menzies) and the Peter Doherty Institute for Infection and Immunity (Doherty Institute) were surprised to see the drug combination wasn't as effective as anticipated.

"The current treatment for MRSA bloodstream infections is an old drug called vancomycin, but it doesn't kill MRSA quickly. So there is an urgent need to find new treatment solutions for this deadly infection," said Professor Joshua Davis from Menzies.

"Many laboratory studies have shown that combining vancomycin with a penicillin-class antibiotic results in improved killing of MRSA."

In this clinical trial involving patients from four countries, half of the participants were randomly allocated to receive vancomycin therapy and the other half received a combination of vancomycin and a penicillin-class antibiotic.

Published today in the journal JAMA, results showed that although the MRSA was killed more quickly, this did not translate to fewer deaths. Surprisingly, combination treatment led to more episodes of kidney injury.

One of the lead researchers, Royal Melbourne Hospital Clinician Researcher at the Doherty Institute and Menzies Associate Professor Steven Tong, said this was a significant finding in the future treatment of MRSA infections.

"Clinicians now have the latest evidence as to what works and what doesn't when treating MRSA bloodstream infections, and this trial shows more is not better," Associate Professor Tong said.

This work will now continue with a National Health and Medical Research Council (NHMRC) \$5 million grant to conduct the *Staphylococcus aureus* Network Adaptive Platform trial (SNAP).

"Golden staph is a bacterium that causes over 5000 bloodstream infections a year in Australia, with a mortality rate of 20 per cent, and yet despite these numbers, there is little evidence to guide best management," Associate Professor Tong said.

"This grant brings together a global collaboration to conduct the largest ever clinical trial for *Staphylococcus aureus* bloodstream infections and address common questions around how to best treat these infections for patients all over the world."

---

<sup>1</sup> Combination Antibiotic Therapy for Methicillin Resistant *Staphylococcus Aureus* infection.



A joint venture between The University of Melbourne and The Royal Melbourne Hospital

### About the Peter Doherty Institute for Infection and Immunity

Finding solutions to prevent, treat and cure infectious diseases and understanding the complexities of the immune system requires innovative approaches and concentrated effort. This is why The University of Melbourne – a world leader in education, teaching and research excellence – and The Royal Melbourne Hospital – an internationally renowned institution providing outstanding care, treatment and medical research – have partnered to create the Peter Doherty Institute for Infection and Immunity (Doherty Institute); a centre of excellence where leading scientists and clinicians collaborate to improve human health globally.

[doherty.edu.au](http://doherty.edu.au)  /DohertyInstitute  @TheDohertyInst #DohertyInstitute

### Menzies School of Health Research

Menzies School of Health Research is one of Australia's leading medical research institutes dedicated to improving Indigenous, global and tropical health. Menzies has a history of over 30 years of scientific discovery and public health achievement. Menzies works at the frontline, joining with partners across the Asia-Pacific as well as Indigenous communities across northern and central Australia. Menzies collaborates to create new knowledge, grow local skills and find enduring solutions to problems that matter.

[menzies.edu.au](http://menzies.edu.au)  /MenziesSchoolofHealthResearch  @MenziesResearch

#### Media Enquiries

Catherine Somerville

Senior Media and Communications Officer  
Doherty Institute

**P** +61 (0) 3 8344 8378  
**M** +61 (0) 422 043 498  
[catherine.somerville@unimelb.edu.au](mailto:catherine.somerville@unimelb.edu.au)

#### Media Enquiries (WEDNESDAY ONLY)

Rebecca Elliott

Communications Manager  
Doherty Institute

**P** +61 (0) 3 8344 8360  
**M** +61 (0) 412 103 306  
[rebecca.elliott@unimelb.edu.au](mailto:rebecca.elliott@unimelb.edu.au)

#### Media Enquiries

Paul Dale

Communications, Marketing and Media Manager  
Menzies School of Health Research

**P** +61 (0) 8 8946 8658  
**M** +61 (0) 439 108 754  
[paul.dale@menzies.edu.au](mailto:paul.dale@menzies.edu.au)